All News

Hospital outpatient prices for standard blood tests, cancer screening and other services varied widely and were sharply higher, on average, than prices charged by ambulatory clinics and independent doctors, an analysis of autoworker health-plan spending across 18 cities has found.

Results indicate that nivolumab is likely to prolong survival in advanced melanoma.

Safety concerns over the PARP inhibitor warranted the request for additional data.

Taking a more strategic approach to payer relationships may be the key to surviving new reimbursements models.

Increasingly, pharmacy benefit managers (PBMs) are refusing to purchase high-cost drugs from manufacturers or include them in their formularies - the lists of drugs that a health plan will cover.

Physician groups are lobbying hard to extend an Obamacare provision that requires state Medicaid programs to pay primary-care physicians at higher Medicare rates to improve access for Medicaid patients. But to persuade congressional Republicans to go along, they are downplaying the fact that the pay bump is part of the Patient Protection and Affordable Care Act.

This week, The American Journal of Managed Care is covering CBI's 7th Summit on Managed Care Market Strategies taking place in Philadelphia, PA. The event includes stakeholder perspectives on improving market access and product value propositions in the evolving healthcare landscape. We continue to spotlight session highlights.

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer (NSCLC) in patients with wild-type epidermal growth-factor receptor (EGFR) tumour status.

This spring as the feds have been drawing up new rules for the program, a pitched battle has broken out between hospitals and drug manufacturers who say the program, known as 340B, is now bloated and badly regulated.

The FDA staff report questioned the unusually poor performance of the control group used in the study.

The Senate introduced legislation this week that would require Medicare to consider patients' finances when deciding whether to punish a hospital for readmission numbers.

Virginia Gov. Terry McAuliffe vowed Friday to bypass the General Assembly and expand Medicaid eligibility for about 400,000 low-income residents on his own.

I'll say it: I think most states, if not all, will be on the Federal exchange by the end of the decade.

With just two weeks under her belt, Health and Human Services (HHS) Secretary Sylvia Mathews Burwell announced a series of changes that will be made to the federal health insurance marketplace following the enrollment and technological problems that ensued the launch of healthcare.gov earlier this year.

Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.

The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made.

A panel asks: "Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?"

Consumer advocacy group Public Citizen on Thursday called on 20 hospital systems to stop partnering with companies that offer low-cost screenings for heart disease and stroke risk, saying the promotions are "unethical" and the exams are more likely to do harm than good.

From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.

For patients who survive cancer, annual medical costs can be nearly double those of non-cancer patients.

Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on ClinicalTrials.gov.

The derivative slowed tumor growth, shrunk tumors, and extended the life of the mice.

BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.

Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.

The US healthcare system's shift from volume- to value-based reimbursement for treatment in order to lower costs and improve patient care is disrupting healthcare business models. The high-profile government—led accountable care organizations (ACOs), which put financial pressure on payers and providers to share responsibility for meeting quality and cost goals, is no exception.

As the bill for providing healthcare in the United States continues to grow, hospitals are finding that many of their expenses can be chalked up to patients with chronic illnesses such as diabetes and heart failure taking avoidable trips to the emergency room (ER).

Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.

The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.

HHS is moving forward with its plan to allow certain hospitals to receive discounts on orphan drugs when they are used for non-orphan conditions despite a court ruling that said the agency did not have the authority to do so.

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).